Trilobio has raised $11.0M in total across 2 funding rounds.
Trilobio's investors include Neotribe Ventures, Project 11, Climate Capital.
Trilobio is a biotechnology company developing a fully integrated lab automation platform, including the Trilobot robot, hardware tools, and Trilobio OS software, to automate genetic engineering, synthetic biology, molecular biology, microbiology, and biochemistry research.[1][2][3] It serves academic labs, therapeutics companies, and industry researchers by solving reproducibility issues—where 77% of biologists fail to reproduce experiments due to human error—and reducing manual setup, integration, and execution times, enabling walk-away automation and higher throughput at affordable prices.[2][3][4][5] The company has shown strong growth momentum, raising $3 million in pre-seed funding in 2021 and an $8 million seed round recently, launching at SLAS2025 with pilot data demonstrating 25-33% throughput increases and 80 hours of saved training time for customers like Triton Bio and Abalone Bio.[2][3][4]
Trilobio was co-founded in 2021 by Roya Amini-Naieni (CEO) and Maximilian Schommer, both named on Forbes' 30 Under 30 list for Manufacturing & Industry, driven by frustrations with existing lab equipment during their research careers.[2][4] Amini-Naieni quit research after recognizing that current tools hindered creativity and efficiency, inspiring her to build automation "by biologists for biologists" that acts as a superpower for scaling experiments.[4][5] Early traction came from developing the self-calibrating Trilobot and no-code Trilobio OS, securing pre-seed funding from Argon Ventures and Lowercarbon Capital, deploying pilots at leading labs, and debuting the platform at SLAS2025 with customer testimonials on real-world impact.[1][2][3]
Trilobio rides the synthetic biology and lab automation wave, where advances in genetic engineering demand reproducible, high-throughput research to tackle climate, disease, and therapeutics challenges, amplified by AI-driven protocol design.[2][4][5] Timing is ideal post-SLAS2025 launch amid a reproducibility crisis (77% failure rate), with market forces like rising R&D costs and labor shortages favoring affordable, plug-and-play automation over fragmented tools.[1][2][5] It influences the ecosystem by democratizing full-lab automation—previously limited to big pharma—fostering protocol sharing via its app store, accelerating discoveries in biotech, and enabling smaller labs to compete, much like cloud computing transformed software development.[3][4]
Trilobio is poised to deploy its platform industry-wide with $8M seed funding, expanding Trilobot fleets, toolkits, and OS intelligence for multi-lab scalability.[3][4] Trends like AI-biology integration and automated wet labs will propel it, potentially capturing share in a market frustrated by 77% irreproducibility, evolving from startup to standard infrastructure for bio-research.[2][5] As automation becomes table stakes, Trilobio's biologist-first approach could spark an explosion of advances, turning lab inefficiencies into a superpower for global challenges—revolutionizing biology as promised from day one.[4][5]
Trilobio has raised $11.0M across 2 funding rounds. Most recently, it raised $8.0M Seed in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $8.0M Seed | Neotribe Ventures, Project 11 | |
| Nov 1, 2023 | $3.0M Seed | Climate Capital, Neotribe Ventures, Project 11 |
